TriSalus Life Sciences exhibits a compelling growth trajectory driven by a differentiated PEDD technology platform with strong clinical validation and reimbursement support. The company's business model is product sales focused, with revenue growth fueled by expanding hospital accounts and enhanced…
TriSalus Life Sciences (TLSI) Q4 2024: 59% Revenue Growth Drives Path to EBITDA Positivity
TriSalus Life Sciences delivered robust 59% full-year revenue growth driven by expanded adoption of its Pressure-Enabled Drug Delivery (PEDD) technology, positioning for positive EBITDA and cash flow in 2025. Strategic reimbursement wins and clinical advancements broaden addressable markets. Execution on commercial expansion and cost discipline underpin confidence in sustained growth trajectory.
Summary
- Commercial Expansion Momentum: Accelerated account growth and utilization underpin strong revenue gains.
- Strategic Reimbursement Wins: New Medicare mapping code unlocks incremental market opportunity.
- Pipeline and Manufacturing Advances: Clinical progress and capacity expansion support future growth.
Business Overview
TriSalus Life Sciences is an oncology-focused medical technology company developing and commercializing Pressure-Enabled Drug Delivery (PEDD) systems to improve therapeutic delivery for solid tumors, primarily in liver and pancreatic cancers. The company generates revenue primarily through sales of its FDA-cleared TriNav infusion system and related devices, with additional value creation from its investigational immunotherapy, nelitolimod. Its commercial business centers on the TriNav portfolio, which addresses complex embolization procedures in liver tumors.
Performance Analysis
TriSalus reported $29.4 million in revenue for the full year 2024, representing a 59% year-over-year increase driven by strong commercial adoption of its TriNav platform. The fourth quarter contributed $8.3 million, up 44% year-over-year and 12% sequentially. Growth was fueled by a 43% increase in unique ordering accounts to 284 and a 10% rise in average units sold per account, reflecting deeper penetration and enhanced utilization. The company’s gross margin remained robust at 85% for Q4 and 86% for the full year, reflecting operational leverage and favorable product mix.
On the expense side, operating costs reflected a strategic shift with a 41% reduction in research and development spending, driven by completion of key Phase 1 trials and a focus on commercialization. Sales and marketing expenses increased 52% year-over-year, supporting expanded salesforce efforts and account development. General and administrative expenses declined 24%, reflecting cost discipline and the non-recurrence of public company transition costs. These factors contributed to a significant reduction in operating losses, with Q4 losses narrowing to $7.6 million from $14.2 million a year prior.
- Sales Growth Drivers: New account openings, increased utilization, and expanded market share to 9% of targeted liver embolization procedures.
- Margin Sustainability: High gross margins above 85% maintained despite growth investments.
- Cost Realignment: R&D cuts and disciplined G&A offset higher sales and marketing spend.
The company ended the year with $8.5 million in cash and secured an additional $10 million drawdown on its $50 million credit facility, ensuring liquidity through 2025 to support growth initiatives.
Executive Commentary
"We achieved 29.4 million in total revenue, marking 59% growth year-over-year, and continue to expect to deliver greater than 50% revenue growth in 2025. Additionally, we anticipate reducing operating expenses by more than 20%, achieving positive EBITDA for the full year, and achieving positive cash flow in the second half of the year."
Mary Zella, President and Chief Executive Officer
"Revenue, driven solely by the continued success of the TriNav device in the U.S., reached 8.3 million in Q4, representing a 44% increase compared to the same period in 2023 and a 12% sequential increase from Q3. We captured 103 new hospital accounts year-to-date and increased account utilization by 10%."
James Young, Chief Financial Officer
Strategic Positioning
1. Expansion of TriNav Portfolio and Market Reach
TriSalus broadened its product offering with the launch of the TriNav LV Infusion System and TriGuide Guiding Catheter, extending its PEDD technology to larger vessel sizes (3.5 to 5.0 mm). This expansion targets a $375 million liver embolization market segment, enabling treatment of more complex cases and enhancing procedural efficiency. The company’s ability to address a wider range of vessel sizes strengthens its competitive positioning and supports deeper market penetration.
2. Reimbursement Advances Unlock Incremental Market
The recent issuance of a new Medicare HCPCS code (C8004) for simulation or mapping procedures using TriNav removes a prior reimbursement barrier for Medicare patients, representing approximately 25% of the payer mix. This code is expected to drive incremental utilization in Medicare populations, expanding the addressable market and providing upside beyond prior guidance, which did not factor in this reimbursement enhancement.
3. Clinical Validation and Pipeline Progress
TriSalus continues to advance its DELIVER clinical program, including the PROTECT registry study evaluating TriNav for non-malignant thyroid goiters, potentially adding an incremental $400 million market opportunity. The company completed enrollment in the PERIO-03 Phase 1 trial for locally advanced pancreatic cancer, with data expected mid-2025. Positive Phase 1 results from the PERIO-01 trial in uveal melanoma liver metastases further validate the investigational immunotherapy nelitolimod, with active efforts to secure strategic partnerships.
4. Manufacturing Capacity and Operational Efficiency
The Westminster manufacturing facility supports current growth and will expand with a clean room addition in Q1 2025, increasing capacity to meet rising demand. Operational improvements have enabled robust gross margins despite increasing sales investments. The company’s manufacturing scalability is a key enabler for sustained revenue growth without significant capital expenditure.
5. Financial Discipline and Capital Position
TriSalus has reduced operating expenses by focusing R&D spend on key clinical milestones and controlling G&A costs. The company’s liquidity position is fortified by a $50 million credit facility with OrbiMed, of which $35 million was accessed by year-end, ensuring funding through 2025. This financial strength underpins confidence in achieving positive EBITDA and cash flow as guided.
Key Considerations
TriSalus’ 2024 performance reflects a strategic pivot emphasizing commercial execution and reimbursement optimization, balanced with clinical innovation and operational scalability.
- Commercial Penetration Focus: Shift from aggressive new account openings to driving utilization in existing accounts aims to optimize revenue per site.
- Reimbursement as Growth Catalyst: Medicare mapping code issuance accelerates adoption in a previously underpenetrated payer segment.
- Clinical Data as Validation: Ongoing trials and real-world evidence reinforce PEDD technology’s therapeutic benefits and broaden indications.
- Cost Structure Realignment: Significant R&D reductions and G&A savings improve operating leverage but require careful balance to sustain innovation.
- Market Share Opportunity: At 9% share of target liver embolization procedures, substantial runway remains for growth in a $1 billion+ addressable market.
Risks
Risks include the pending completion of the 2024 audited financial statements, which may introduce adjustments related to stock-based compensation and clinical R&D expense timing. Market adoption of new products and reimbursement codes may be slower than anticipated. Clinical trial outcomes, particularly for nelitolimod, remain uncertain, and partnership negotiations may not materialize. Competitive dynamics in interventional oncology and regulatory changes could also impact growth.
Forward Outlook
For Q1 2025, management refrained from providing detailed guidance but anticipates some lumpiness in quarterly growth, with a potential back-end weighted revenue cadence. For the full year 2025, TriSalus reaffirmed guidance to achieve:
- Greater than 50% revenue growth driven by market share gains, new product launches, and expanded reimbursement.
- Gross margins exceeding 87% supported by operational efficiencies.
- More than 20% reduction in operating expenses, reflecting lower R&D and G&A costs.
- Positive EBITDA for the full year and positive cash flow in the second half of 2025.
Management highlighted that new Medicare reimbursement and ongoing clinical programs are expected to be key growth drivers, with manufacturing capacity expansion supporting increased demand.
Takeaways
TriSalus Life Sciences is executing a disciplined growth strategy balancing commercialization, reimbursement expansion, and clinical innovation. The company’s robust revenue growth and improving cost structure set a clear path to profitability and cash flow positivity in 2025, a critical inflection point for investor value realization.
- Commercial Execution Strength: Expanding account base and utilization gains validate market acceptance of TriNav PEDD technology.
- Reimbursement Unlocks New Markets: Medicare mapping code issuance creates incremental revenue potential not previously modeled.
- Pipeline and Manufacturing Catalysts: Clinical trial data and capacity expansion position TriSalus for sustained growth and competitive differentiation.
Conclusion
TriSalus demonstrated strong operational momentum in 2024 with significant revenue growth and margin resilience. The company’s strategic focus on commercial growth, reimbursement wins, and clinical advancement underpins its confidence in achieving profitability and cash flow milestones in 2025, marking a critical step in its evolution as a medtech growth story.
Industry Read-Through
TriSalus’ progress highlights the growing importance of innovative delivery technologies in interventional oncology, particularly those that enhance therapeutic precision and patient outcomes. The reimbursement environment remains a critical lever for adoption, as evidenced by the impact of Medicare coding decisions. Other device companies targeting complex tumor embolization may face similar pressures to demonstrate clinical and economic value to unlock broader payer coverage. The integration of immunotherapies with device platforms, as pursued by TriSalus, signals a trend toward combination approaches in oncology that could reshape treatment paradigms.